Back to results
US 2024/0391999 A1Published application
Treatment with anti-kir3dl2 agents
AssigneeInnate Pharma
InventorsCARINE PATUREL, HELENE SICARD
Life of this patent
Estimating the term…
Abstract
This invention relates to the use of KIR3DL2-targeting agents for the treatment of CTCL. The invention provides advantageous treatment regimens using anti-KIR3DL2 antibodies for the treatment of CTCL, notably in first-line CTCL.
Claims8
(canceled)
A method of treating a cutaneous T-cell lymphoma (CTCL) comprising administering an antibody comprising:
- a heavy chain CDR 1, 2 and 3 (HCDR1, HCDR2, HCDR3) comprising SEQ ID NO:
- 2 (HCDR1), SEQ ID NO:
- 3 (HCDR2) and SEQ ID NO:
- 4 (HCDR3) respectively, and a light chain CDR 1, 2 and 3 (LCDR1, LCDR2, LCDR3) comprising SEQ ID NO:
- 5 (LCDR1), 6 (LCDR2) and 7 (LCDR3) respectively to a subject having a CTCL.
2 more elements
Dependencies are inferred from the claim text.